LM11A-31

LM11A-31
Clinical data
Other namesLM-11A-31
Legal status
Legal status
  • Investigational
Identifiers
  • (2S,3S)-2-Amino-3-methyl-N-(2-morpholin-4-ylethyl)pentanamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H25N3O2
Molar mass243.351 g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@@H](C(=O)NCCN1CCOCC1)N
  • InChI=1S/C12H25N3O2/c1-3-10(2)11(13)12(16)14-4-5-15-6-8-17-9-7-15/h10-11H,3-9,13H2,1-2H3,(H,14,16)/t10-,11-/m0/s1
  • Key:YNMUTYLWSRFTPX-QWRGUYRKSA-N

LM11A-31 is an experimental drug developed for Alzheimer's disease and Huntington's disease.[1][2][3][4][5][6][7][8]

References

  1. ^ Simmons, Danielle A.; Knowles, Juliet K.; Belichenko, Nadia P.; Banerjee, Gargi; Finkle, Carly; Massa, Stephen M.; Longo, Frank M. (2014-08-25). "A Small Molecule p75NTR Ligand, LM11A-31, Reverses Cholinergic Neurite Dystrophy in Alzheimer's Disease Mouse Models with Mid- to Late-Stage Disease Progression". PLOS ONE. 9 (8) e102136. Bibcode:2014PLoSO...9j2136S. doi:10.1371/journal.pone.0102136. ISSN 1932-6203. PMC 4143160. PMID 25153701.
  2. ^ Elshaer, Sally L.; Alwhaibi, Abdulrahman; Mohamed, Riyaz; Lemtalsi, Tahira; Coucha, Maha; Longo, Frank M.; El-Remessy, Azza B. (2019). "Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway". Diabetologia. 62 (8): 1488–1500. doi:10.1007/s00125-019-4885-2. ISSN 0012-186X. PMC 8808141. PMID 31073629.
  3. ^ Simmons, Danielle A.; Mills, Brian D.; Butler III, Robert R.; Kuan, Jason; McHugh, Tyne L.M.; Akers, Carolyn; Zhou, James; Syriani, Wassim; Grouban, Maged; Zeineh, Michael; Longo, Frank M. (2021). "Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31". Neurotherapeutics. 18 (2). Elsevier BV: 1039–1063. doi:10.1007/s13311-021-01023-8. ISSN 1878-7479. PMC 8423954. PMID 33786806.
  4. ^ Nasoohi, Sanaz; Tayefeh Ghahremani, Pargol; Alehossein, Parsa; Elyasizadeh, Siyamak; BaniArdalan, Soha; Ismael, Saifudeen; Vatanpour, Hossein; Ahmadiani, Abolhassan; Ishrat, Tauheed (2023). "The p75 neurotrophin receptor inhibitor, LM11A-31, ameliorates acute stroke injury and modulates astrocytic proNGF". Experimental Neurology. 359 114161. Elsevier BV. doi:10.1016/j.expneurol.2022.114161. ISSN 0014-4886. PMID 35787888.
  5. ^ Simmons, Danielle A; James, Michelle L; Belichenko, Nadia P; Semaan, Sarah; Condon, Christina; Kuan, Jason; Shuhendler, Adam J; Miao, Zheng; Chin, Frederick T; Longo, Frank M (2018-08-15). "TSPO–PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31". Human Molecular Genetics. 27 (16): 2893–2912. doi:10.1093/hmg/ddy202. ISSN 0964-6906. PMC 6077813. PMID 29860333.
  6. ^ Nguyen, Thuy-Vi V.; Crumpacker, Rachel H.; Calderon, Kylie E.; Garcia, Frankie G.; Zbesko, Jacob C.; Frye, Jennifer B.; Gonzalez, Selena; Becktel, Danielle A.; Yang, Tao; Tavera-Garcia, Marco A.; Morrison, Helena W.; Schnellmann, Rick G.; Longo, Frank M.; Doyle, Kristian P. (2021-12-10). "Post-Stroke Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Attenuates Chronic Changes in Brain Metabolism, Increases Neurotransmitter Levels, and Improves Recovery". Journal of Pharmacology and Experimental Therapeutics. 380 (2). American Society for Pharmacology & Experimental Therapeutics (ASPET): 126–141. doi:10.1124/jpet.121.000711. ISSN 0022-3565. PMC 11048261. PMID 34893553.
  7. ^ Yin, Guo Nan; Ock, Jiyeon; Limanjaya, Anita; Minh, Nguyen Naht; Hong, Soon-Sun; Yang, Tao; Longo, Frank M.; Ryu, Ji-Kan; Suh, Jun-Kyu (2021). "Oral Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Improves Erectile Function in a Mouse Model of Cavernous Nerve Injury". The Journal of Sexual Medicine. 18 (1): 17–28. doi:10.1016/j.jsxm.2020.10.015. PMID 33243690.
  8. ^ Shanks, Hayley R. C.; Börjesson-Hanson, Anne; Windisch, Manfred; Massa, Stephen M.; Longo, Frank M.; Schmitz, Taylor W. (December 2022). "Age-dependent effects of the p75 neurotrophin receptor modulator LM11A-31 on Alzheimer's disease biomarkers in a 26-week safety and exploratory endpoint trial". Alzheimer's & Dementia. 18 (S10) e069079. doi:10.1002/alz.069079.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.